Newsroom


Bioventus Receives ANVISA Approval to Market DUROLANE in Brazil and Selects Pfizer as Exclusive Distribution Partner

HOOFDDORP, THE NETHERLANDS – October 2, 2018 – Bioventus, a global leader in orthobiologic solutions, has received approval from Agência Nacional de…

Read More

Bioventus Enters Into Definitive Agreement to Divest BMP Program

DURHAM, NC – July 23, 2018 – Bioventus, a global leader in orthobiologic solutions, has entered into a definitive agreement to divest its next…

Read More

Bioventus Launches DUROLANE in the US

DURHAM, NC - March 5, 2018 – Bioventus, a global leader in orthobiologic solutions, today launched DUROLANE, its single-injection, hyaluronic acid…

Read More

Bioventus to Co-Develop Next Generation Bone Allograft with LifeLink

DURHAM, NC – February 26, 2018 – Bioventus, a global leader in orthobiologic solutions, has entered into an agreement with LifeLink Tissue Bank, a…

Read More

Bioventus to Continue Distributing SUPARTZ FX Through 2028

DURHAM, NC - February 12, 2018 – Bioventus, a global leader in orthobiologic solutions, has entered into an extension of its agreement with Seikagaku…

Read More

Additional Strategic Funding for CartiHeal’s Ongoing AGILI-C™ IDE Clinical Study $2.5M boost by Bioventus brings latest investment round to $21M

KFAR SABA, ISRAEL and DURHAM, NC– January 31, 2018 - CartiHeal, developer of the proprietary Agili-C implant for the treatment of joint surface…

Read More

Bioventus Launches New Website for EXOGEN®

DURHAM, NC– January 25, 2018 – Bioventus, a global leader in orthobiologics, today has launched a new version of EXOGEN.com, the product website for…

Read More

Bioventus Announces First Patients Enrolled in BONES Study for EXOGEN®

DURHAM, NC– September 13, 2017 – Bioventus, a global leader in orthobiologics, today announced the first patients have been enrolled in its BONES…

Read More

Bioventus Receives US FDA Approval for DUROLANE®

DURHAM, NC- September 5, 2017 – Bioventus, a global leader in orthobiologic solutions, today announced it has received US FDA approval for DUROLANE,…

Read More

Bioventus Names Greg Anglum SVP and CFO, Tony D’Adamio SVP and General Counsel

DURHAM, NC- August 7, 2017 – Bioventus®, a leader in orthobiologic solutions, today announced two changes to its executive leadership team. Greg…

Read More

Search News


Media Inquiries


Thomas Hill
Director of Corporate Communications
919.474.6715
[email protected]

Download Library


Corporate and Brand Logos
Download Now

Product Images
Download Now